SCHEMBL9907320

SCHEMBL9907320

COC(=O)c1ccc2ccnc(C)c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.56
ALOX15 P16050 2/20 0.50
HTT P42858 1/20 0.50
KDM4E B2RXH2 5/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
KDM6B O15054 1/20 0.49
KDM5C P41229 1/20 0.49
KDM4C Q9H3R0 1/20 0.49
KDM2A Q9Y2K7 1/20 0.49
KDM3A Q9Y4C1 1/20 0.49
LCK P06239 1/20 0.48
NQO2 P16083 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
XDH P47989 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
CYP19A1 P11511 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9106372 0.84 LCK (0.51) DYRK1AALOX15HTTKDM4EL3MBTL1
SCHEMBL2671189 0.83 ALOX15 (0.49) DYRK1AALOX15HTTKDM4EL3MBTL1
SCHEMBL17053153 0.82 PLAU (0.59) DYRK1AHTTKDM4EL3MBTL1KDM6B
SCHEMBL9907587 0.79 LCK (0.53) DYRK1AALOX15HTTKDM4EL3MBTL1
SCHEMBL9907334 0.79 CYP19A1 (0.49) ALOX15HTTKDM4EKDM6BKDM5C
SCHEMBL3357348 0.76 KDM4C (0.49) ALOX15HTTKDM4EL3MBTL1KDM6B
SCHEMBL9108406 0.76 KDM4E (0.42) DYRK1AALOX15HTTKDM4EL3MBTL1
SCHEMBL27185226 0.76 DYRK1A (0.50) DYRK1AALOX15HTTKDM4EL3MBTL1
SCHEMBL16502654 0.76 ALOX15 (0.48) DYRK1AALOX15HTTL3MBTL1LCK
SCHEMBL12875031 0.76 ALOX15 (0.45) DYRK1AALOX15HTTKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS BRIDGE MEDICINES 2025-05-01 US disclosed
CN-117858877-A C-linked inhibitors of ENL/AF9 YEATS 桥梁药品有限公司 2024-04-09 CN disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E DYRK1A 3985/4885ALOX15 1101/4885HTT 970/4885
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS MLLT3, MLLT1, YEATS2 DYRK1A 3304/4885ALOX15 2807/4885HTT 3617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.